GrayMatters Health Expands FDA-Cleared PTSD Treatment to U.S. Clinics

GrayMatters Health (GMH), a leader in digital mental health treatments based on brain biomarkers, is increasing patient access to its Prism for PTSD™ therapy. This device is the first FDA-cleared self-neuromodulation treatment specifically for post-traumatic stress disorder (PTSD), offering an innovative way to manage this challenging condition.

Prism for PTSD™ utilizes patented technology that focuses on an amygdala-based biomarker to help patients regulate brain activity linked to PTSD. This self-neuromodulation method allows patients to take an active role in their recovery. Now available in clinics across the U.S., Prism for PTSD™ provides personalized therapy based on unique digital biomarkers associated with mental health disorders. Some of the new clinics offering this treatment include Breakthru Psychiatric Solutions in Sandy Springs and Alpharetta, GA, Forensic & Clinical Psychiatry in Seattle, WA, and the Institute for Advanced Psychiatry in Fort Worth, TX.

In a pivotal clinical trial published in the Journal of Psychiatry Research, Prism for PTSD™ showed promising results, with 67% of participants reporting significant improvement in their PTSD symptoms and response rates exceeding 80% in certain sub-populations. The therapy was associated with only mild, transient side effects like headaches and fatigue, which resolved without intervention. A new analysis presented at the International Society for Traumatic Stress Studies indicated significant benefits across all PTSD symptom clusters.

Click here to read the original news story.